JPMorgan Chase & Co. Lowers Adaptive Biotechnologies (NASDAQ:ADPT) Price Target to $19.00

Key Points

• JPMorgan cut its price target on Adaptive Biotechnologies from $21 to $19 but kept an "overweight" rating, with the new target implying roughly a 31.7% upside from the cited stock level.
• Q1 results beat estimates: ADPT reported EPS of ($0.13) vs. ($0.16) expected and revenue of $70.87M (up ~35% year-over-year), which lifted the shares about 4.7% to $14.43 on the day.
• Profitability and ownership concerns remain: the company still posts negative net margin (~21.5%) and ROE (~46.7%), insiders sold ~2.42M shares (~$34.2M) in recent months, while analysts hold a "Moderate Buy" consensus with a $20 average target.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) had its target price decreased by JPMorgan Chase & Co. from $21.00 to $19.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s target price suggests a potential upside of 31.67% from the company's current price.

Other equities research analysts have also issued reports about the company. BTIG Research reissued a "buy" rating and set a $22.00 price target on shares of Adaptive Biotechnologies in a research note on Wednesday. Wall Street Zen lowered Adaptive Biotechnologies from a "buy" rating to a "hold" rating in a research note on Saturday, March 7th. Guggenheim reissued a "buy" rating and set a $21.00 price target on shares of Adaptive Biotechnologies in a research note on Wednesday. Piper Sandler set a $21.00 price objective on Adaptive Biotechnologies in a report on Friday, February 6th. Finally, TD Cowen raised their price objective on Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a "buy" rating in a report on Wednesday. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Adaptive Biotechnologies presently has a consensus rating of "Moderate Buy" and a consensus target price of $20.00.

Adaptive Biotechnologies Trading Up 4.7%

Shares of ADPT stock traded up $0.65 on Wednesday, reaching $14.43. 4,896,838 shares of the company's stock were exchanged, compared to its average volume of 1,967,962. Adaptive Biotechnologies has a 52 week low of $8.38 and a 52 week high of $20.76. The stock has a market capitalization of $2.31 billion, a PE ratio of -36.07 and a beta of 2.16. The company's fifty day simple moving average is $14.32 and its 200 day simple moving average is $15.92.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.16) by $0.03. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The firm had revenue of $70.87 million during the quarter, compared to analyst estimates of $61.03 million. During the same period last year, the company earned ($0.20) EPS. Adaptive Biotechnologies's quarterly revenue was up 35.1% compared to the same quarter last year. As a group, sell-side analysts predict that Adaptive Biotechnologies will post -0.5 earnings per share for the current fiscal year.

Insider Activity at Adaptive Biotechnologies

In other news, insider Sharon Benzeno sold 63,103 shares of Adaptive Biotechnologies stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $13.17, for a total value of $831,066.51. Following the transaction, the insider directly owned 272,751 shares in the company, valued at approximately $3,592,130.67. This trade represents a 18.79% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Julie Rubinstein sold 141,583 shares of Adaptive Biotechnologies stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $13.29, for a total value of $1,881,638.07. Following the completion of the transaction, the chief operating officer owned 516,610 shares in the company, valued at $6,865,746.90. This represents a 21.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 2,417,168 shares of company stock worth $34,153,000 over the last three months. Corporate insiders own 5.70% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ADPT. Westfield Capital Management Co. LP purchased a new position in shares of Adaptive Biotechnologies in the 4th quarter valued at $65,942,000. Price T Rowe Associates Inc. MD increased its holdings in shares of Adaptive Biotechnologies by 303.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company's stock valued at $71,252,000 after acquiring an additional 3,299,635 shares during the period. Ameriprise Financial Inc. increased its holdings in shares of Adaptive Biotechnologies by 84.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company's stock valued at $89,337,000 after acquiring an additional 2,731,648 shares during the period. Invesco Ltd. increased its holdings in shares of Adaptive Biotechnologies by 248.8% in the 4th quarter. Invesco Ltd. now owns 3,107,653 shares of the company's stock valued at $50,468,000 after acquiring an additional 2,216,595 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its holdings in shares of Adaptive Biotechnologies by 544.0% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company's stock valued at $36,523,000 after acquiring an additional 2,062,282 shares during the period. 99.17% of the stock is currently owned by hedge funds and other institutional investors.

Key Adaptive Biotechnologies News

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Q1 results beat consensus — Adaptive reported EPS of ($0.13) vs. ($0.16) expected and revenue of $70.87M (up ~35% YoY), a clear topline beat that supports commercial traction and drove investor optimism. GlobeNewswire Q1 Results
• Positive Sentiment: Broker support lifted sentiment — Guggenheim reaffirmed a Buy with a $21 PT and BTIG reiterated Buy with a $22 PT, both implying ~45–53% upside from current levels and reinforcing the bullish case after the print. Benzinga (analyst notes)
• Neutral Sentiment: Management commentary and call transcripts available — Earnings call transcripts (Seeking Alpha / InsiderMonkey) detail management’s take on MRD adoption across clinical testing and drug development, useful for judging durability of revenue growth but not an immediate valuation changer. Seeking Alpha Transcript
• Neutral Sentiment: Analyst write-ups and metric reviews — Coverage from Zacks and MarketBeat breaks down key metrics vs. estimates (revenue beat, margin dynamics) and provides context; these help investors but don’t change the fundamental profitability picture. Zacks analysis
• Negative Sentiment: Still unprofitable with negative margins and ROE — Despite revenue growth, Adaptive reported a negative net margin (~21%) and negative return on equity (~46.7%); sell-side consensus still models a full-year loss (around -$0.50 EPS), which caps near-term valuation expansion until consistent profitability or stronger growth visibility emerges. MarketBeat earnings summary

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.